Core Insights - Sol-Gel Technologies Ltd. reported a quarterly loss of $0.01 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.13, and an improvement from a loss of $0.21 per share a year ago, indicating a 92.31% earnings surprise [1] - The company achieved revenues of $5.36 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 99.29%, compared to revenues of $0.21 million in the same quarter last year [2] - Sol-Gel Technologies shares have declined approximately 54.8% year-to-date, contrasting with the S&P 500's gain of 24.7% [3] Financial Performance - Over the last four quarters, Sol-Gel Technologies has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $1.83 million, and for the current fiscal year, it is -$0.57 on revenues of $8.5 million [7] Industry Outlook - The Medical - Generic Drugs industry, to which Sol-Gel Technologies belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of Sol-Gel Technologies' stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]

Core Insights - Sol-Gel Technologies, Ltd. has appointed Mori Arkin as interim CEO effective January 1, 2025, replacing founder Dr. Alon Seri-Levy, who will continue as a consultant for at least one year [2] - The company is conducting a Phase 3 clinical trial of SGT-610 for Gorlin Syndrome, with over 40 clinical sites activated and top-line results expected in the second half of 2026 [2][4] - Financial results for Q3 2024 show total revenue of $5.4 million, a significant increase from $0.2 million in Q3 2023, primarily driven by licensing revenue [5] Corporate Developments - The transfer of Sol-Gel's Ordinary Shares from The Nasdaq Global Market to The Nasdaq Capital Market was approved, effective November 15, 2024, to provide a second 180-day compliance period for the minimum bid price rule [2] - A new agreement with Padagis will enhance Sol-Gel's cash position by approximately $6 million through eight quarterly payments and low single-digit royalties from sales of a generic drug product [2] - Sol-Gel signed a license agreement for the commercialization of TWYNEO and EPSOLAY in South Korea, with expected upfront and regulatory milestone payments of up to $3.7 million [2] Clinical Trials and Product Pipeline - The Phase 3 study of SGT-610 is ongoing with approximately 140 subjects enrolled across 40 clinical centers, targeting a market exceeding $300 million annually if approved [2][4] - The proof-of-concept study for SGT-210 in patients with Darier disease is also ongoing, with a market potential estimated between $200 million to $300 million [2][4] - SGT-210 is currently being used in a compassionate use treatment for a pediatric patient, showing promising preliminary results [3] Financial Performance - Research and development expenses for Q3 2024 were $4.8 million, slightly up from $4.7 million in Q3 2023, primarily due to increased clinical trial expenses [6] - General and administrative expenses decreased to $1.4 million from $1.9 million in the same period last year, attributed to cost-saving measures [7] - The net loss for Q3 2024 was $0.4 million, a significant improvement compared to a net loss of $5.7 million in Q3 2023 [8] Cash Position - As of September 30, 2024, Sol-Gel had $14.6 million in cash and cash equivalents, and $14.6 million in marketable securities, totaling $29.2 million [8] - The company expects its cash resources to fund operations into the first quarter of 2026 [8]

Core Viewpoint - Sol-Gel Technologies Ltd. (SLGL) has experienced a recent downtrend, losing 8.4% over the past two weeks, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest and positive earnings outlook from analysts [1]. Group 1: Technical Analysis - A hammer chart pattern was formed in the last trading session, indicating that bulls may have countered the bears, suggesting potential support for the stock [1]. - The hammer pattern signals a possible bottom in a downtrend, indicating that selling pressure may be exhausting [2]. - Hammer candles can appear on various timeframes and are used by both short-term and long-term investors, but should be combined with other bullish indicators for confirmation [2]. Group 2: Fundamental Analysis - There has been a positive trend in earnings estimate revisions for SLGL, with a 31.3% increase in the consensus EPS estimate for the current year over the last 30 days, indicating expected better earnings [3]. - SLGL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [3]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are beginning to improve, further supporting the potential for a trend reversal [3].

Sol-Gel Technologies Ltd. (SLGL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked b ...

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Topline results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product ge ...

Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 135%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.23, delivering a surprise of -53.33%. Over the last four quarters, ...

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Topline results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA)drug product gen ...

These new collaborations are in addition to existing agreements that Sol-Gel has already signed in the US, Canada and China, emphasizing the trust and significant commercial potential for both drugs. About EPSOLAY® and TWYNEO® TWYNEO is a topical cream containing a fixed-dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, cream for the treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. TWYNEO is the first acne treatment that contains a fixed-dose combination of ...

Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -53.33%. A quarter ago, it was expected that this company would post a loss of $0.16 per share when it actually produced a loss of $0.17, delivering a surprise of -6.25%. Over the last four quarters, the company ...

Financial Results for the First Quarter Year Ended March 31st, 2024 NESS ZIONA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large- category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the first quarter ended March 31, 2024 and provided a ...